Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
21. April 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
19. April 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company...
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
14. April 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
12. April 2022 08:00 ET
|
Cocrystal Pharma, Inc.
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal...
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
23. März 2022 16:05 ET
|
Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
22. März 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group...
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
10. März 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy...
Cocrystal Pharma to Participate in Upcoming Investment Conferences
03. März 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor...
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
27. Januar 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity...
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
06. Januar 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP)...